CytoSorbents Corporation (CTSO)

[techxen]

Agree, this is a big deal
and a difficult thing that the company has achieved. For new and innovative medical devices the reimbursement decision process is often based on established pharmaceutical pathways meaning strong clinical evidence based on clinical trials - it is tricky and not that straightforward. According to an article in the Negative Pressure Wound Therapy Journal in the April issue this year, those EU countries with DRG-systems can take at least two years for an innovative device to trigger the grouping of patients into a better paid/dedicated DRG (one year for data collection and another for analysis). You can tell by Dr. Steiner's choice of words: "The relatively short time frame in which this specific reimbursement code was granted is remarkable..", that they see this as a significant achievement.

Having a dedicated product reimbursement code going into 2017 is going to be key to widespread adoption of the device next year in Germany and hopefully to some of the other countries that have DRG-based systems like Switzerland and UK.